Type 2 diabetes mellitus.
For initial therapy: The recommended starting dose of sensimet is 2 mg/500 mg administered once or twice daily.For patients inadequately controlled on Metformin monotherapy: Starting dose is 4 mg Rosiglitazone (total daily dose) plus the dose of Metformin already being taken. For patients inadequately controlled on Rosiglitazone monotherapy: Starting dose is 1,000 mg Metformin (total daily dose) plus the dose of Rosiglitazone already being taken.
When a patient stabilized on any diabetic regimen is exposed to stress such as fever, trauma, infection, or surgery, a temporary loss of glycemic control may occur. At such times, it may be necessary to withhold combination of Rosiglitazone & Metformin & temporarily administer insulin. Combination of Rosiglitazone & Metformin should be used with caution in patients with edema.
Rosiglitazone: Upper resp tract infections, nasopharyngitis, sinusitis, constipation, hypertension, back pain, increased risk of bone fractures (especially in females), fatigue, hypoglycaemia; dose-related wt gain, oedema & anaemia; macular ordema, hepatitis, elevated liver enzymes, hyperlipedaemia. Metformin: Anorexia, nausea, vomiting, diarrhoea, wt loss, flatulence, occasional metallic taste; weakness; hypoglycaemia; rash, malabsorption of vit B12. CHF, possible increased risk of myocardial ischaemia; lactic acidosis in presence of renal failure & alcoholism.
Pregnancy Category C: Combination of Rosiglitazone & Metformin should not be used during pregnancy unless the potential benefit justifies the potential risk to the fetus. Combination of Rosiglitazone & Metformin should not be administered to a nursing woman.
.png&w=384&q=75)